On April 25, 2024 TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, reported that its IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting taking place May 31-June 4, 2024 in Chicago, IL (Press release, TuHURA BioPharma, APR 25, 2024, View Source [SID1234642345]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Title: Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
Abstract #: 9592
Presenter: Andrew Brohl, MD, H. Lee Moffitt Cancer Center and Research Institute
Session Title: Melanoma/Skin Cancers
Session Date and Time: Saturday, June 1, 2024 at 1:30 PM CDT
Location: Hall A, Poster #376
TuHURA recently announced it has entered into a definitive agreement for an all-stock transaction with Kintara Therapeutics, Inc. ("Kintara") to form a company combining expertise and resources to advance a risk diversified late-stage oncology pipeline. In conjunction with the execution of the definitive agreement, TuHURA entered into subscription agreements for a $31 million financing. The combined company will focus on advancing TuHURA’s personalized cancer vaccine(s) and first-in-class bi-functional Antibody Drug Conjugates ("ADCs"), two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market under the ticker "HURA". The transaction is subject to customary closing conditions, including stockholder approval of both companies, and is expected to close in the third quarter of 2024.